Conference Coverage

Checkmate 214: Upfront nivo/ipi bests TKI in advanced RCC

Publish date: September 28, 2017

 

AT ESMO 2017

Pages

Recommended Reading

Savolitinib improves PFS in some with MET-driven papillary renal cell carcinoma
MDedge Hematology and Oncology
No survival benefit with adjuvant girentuximab in high-risk RCC
MDedge Hematology and Oncology
Sequential pazopanib and everolimus nets good survival in metastatic RCC
MDedge Hematology and Oncology
FDA advisory committee to consider adjuvant sunitinib for RCC
MDedge Hematology and Oncology
Exelixis seeks expanded indication for cabozantinib in RCC
MDedge Hematology and Oncology
Adverse effects of PD-1/PD-L1 inhibitors varied by tumor type in systematic review
MDedge Hematology and Oncology
Tivozanib gets EU approval for advanced RCC
MDedge Hematology and Oncology
Pembrolizumab, nivolumab linked to 3% rate of neurologic events
MDedge Hematology and Oncology
PROTECT trial: No DFS benefit with adjuvant pazopanib for high-risk RCC
MDedge Hematology and Oncology
FDA approves biosimilar to bevacizumab
MDedge Hematology and Oncology